Comparative Pharmacology
Head-to-head clinical analysis: POSFREA versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSFREA versus VAGISTAT 1.
POSFREA vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
IV 4 mg/kg once daily; infused over 90 minutes.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal